Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCZH5B)

Drug Name

GS-9256 Drug Info

Synonyms

GS-9256; UNII-8V42Y78HRU; 1001094-46-7; GS 9256; 8V42Y78HRU; [[8-chloro-2-[2-(isopropylamino)thiazol-4-yl]-7-methoxy-4-quinolyl]oxy-(cyclopentoxycarbonylamino)-dioxo-[ ]yl]-[(2,6-difluorophenyl)methyl]phosphinic acid; GS9256; SCHEMBL9987287; CHEMBL1956820; DTXSID70142946; DB12876

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Phase 2	[1]

Cross-matching ID

PubChem CID: 24823649
CAS Number: CAS 1001094-46-7
TTD Drug ID: DMCZH5B

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Human immunodeficiency virus Protease (HIV PR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Saquinavir	DMG814N	Human immunodeficiency virus infection	1C62	Approved	[2]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[3]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[4]
Atazanavir	DMSYRBX	Human immunodeficiency virus infection	1C62	Approved	[5]
Amprenavir	DMLMXE0	Human immunodeficiency virus infection	1C62	Approved	[6]
Darunavir	DMN3GCH	Human immunodeficiency virus infection	1C62	Approved	[7]
Tipranavir	DM8HJX6	Human immunodeficiency virus infection	1C62	Approved	[8]
Fosamprenavir	DM4W9B3	Human immunodeficiency virus infection	1C62	Approved	[9]
BI 201335	DM3MXT8	Hepatitis C virus infection	1E51.1	Phase 3	[10]
BMS 650032	DMQI43G	Hepatitis C virus infection	1E51.1	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Protease (HIV PR)	TT5FNQT	POL_HV1B1	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of Gilead (2011).
2	PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63.
3	Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80.
4	Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20.
5	Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9.
6	Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503.
7	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410.
10	2011 Pipeline of Boehringer Ingelheim Pharma.
11	2011 Pipeline of Bristol-Myers Squibb.